Pfizer's (PFE) Talzenna plus Xtandi significantly improves radiographic progression-free survival in metastatic prostate cancer; meets primary endpoint with significant improvement in RPFS

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

3M (MMM) acquires Madison Fire & Rescue and combines with Scott safety deal valued at USD 1.95bln; to receive USD 700mln cash proceeds upon closing

Russian Energy Ministry says fuel export ban may be introduced preventively in case of high prices

Pfizer's (PFE) Talzenna plus Xtandi significantly improves radiographic progression-free survival in metastatic prostate cancer; meets primary endpoint with significant improvement in RPFS

Accenture (ACN) Q2 2026 (USD): EPS 2.93 (exp. 2.85), Revenue 18bln (exp. 17.84bln)

Newsquawk Daily US Opening News - 19th March 2026

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Pfizer's successful trial of Talzenna plus Xtandi in metastatic prostate cancer highlights potential for significant revenue growth through advanced oncology treatments. This positive data may boost investor confidence in PFE's pipeline and could lead to an upward revision in future earnings estimates as the product approaches market introduction.

Related headlines

The feed had this first.

Use the Platform